3.82↑-0.03 (-0.78%)
04:01 PM,29th Sep 2023BSE : 524661
NSE :
Sector : Health care
ISIN Code : INE331C01017
Last Updated: Sep 29 2023 | 04:01 PM IST
Market Cap (₹ Cr) | 0 |
Turnover (₹ Cr) | 0.00 |
Volume (Shares) | |
Face Value | 10 |
52-WK High | 0.00 |
52-WK High Date | Invalid date |
52-WK Low | 0.00 |
52-WK Low Date | Invalid date |
All Time High | 0.00 |
All Time High Date | Invalid date |
All Time Low | 0.00 |
All Time Low Date | Invalid date |
Incorporated on 4 Jun.'92 Welcure Drugs And Pharmaceuticals (WDPL) was promoted by D C Jain Sanjeev Jain and Sandeep Jain. The promoters have interests in other companies such as Paam Pharmaceuticals Pioneer Products Alirox Abrasives A K Laboratories etc. The company is managed by managing director D C Jain.WDPL had come out with a Rs 4-cr public issue in Aug.'94 to part-finance the Rs 7-cr project to manufacture bulk drugs in Rajasthan and finance investments in a subsidiary A K Laboratories (AKL). The company has also submitted the letter of offer for a Rs 7.09-cr rights issue of equity shares in Jan.'96 to finance its expansion programmes.Products of WDPL include bulk drugs such as ampicillin and trimethoprim drugs intermediates and pharmaceutical formulations. It has decided to add amoxycillin and cloxacillin to its range with provision to manufacture ibuprofen. It manufactures over a hundred varieties of tablets capsules and dry syrups sulpha drugs vitamins analgesics etc. Its subsidiary AKL manufactures 6-APA a key drug intermediate in the manufacture of semi-synthetic penicillin. The company has decided to set up new sections of paediatrics and veterinary drugs and to diversify into ointments and liquid syrups. The new products of the company WELSTAP X- CLOX ETHAMBUTOL RIFA- Z CETIRIZIN NORTIN have been well accepted in the market.The Company has entered into a collaboration agreement with a russian company to act as their sole selling agent for a unique medicine Stevioside an alternate to sugar Saccharin and Aspartame.The Company has added a new liquid oral plant in Bhiwadi Rajasthan. It has obtained ISO 9002 certification with double accredition from ABS Quality Evaluation Inc Texas and by Registrar of Accredition Board of USA. Welcure has also entered into an agreement with Bihar Drugs and Chemicals Ltd a government of Bihar undertaking for manufacturing their products in its factory on loan basis.During the year 2000-01 the company had launched some products like CEZENDIMCIN PLUSOXINSPASWIN etc.The company has entered into technical collaboration agreement with Advanced Medical Care Inc New Jersey USA for setting up of joint venture facilities in the existing plant of the company.During the year 2001-02 the company had launched products like B-ZEX DMART PLUS DRALPIN DUKESPAS DUBAMOL HISTACURE KUFFWEL KINGSPAS LANAX PETRIMAX PEEROSCAM RENACT SARVO WELCEE WELGESIC WELIC WELOXY WELRELEEF X-DRYL.The company has changed its marketing policy from Sales through Wholesale Distributors to Sales at Doorstep by reaching every corner of the country and by putting dual force on Sales-through sales personnel on one hand and through stockists and distributors on the other hand.
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 5 |
EPS - TTM (₹) [S] | 0.00 |
P/E Ratio (X) [S] | 3.26 |
Face Value (₹) | 10 |
Latest Dividend (%) | - |
Latest Dividend Date | - |
Dividend Yield (%) | - |
Book Value Share (₹) [S] | 1.17 |
P/B Ratio (₹) [S] | 3.26 |
[*C] Consolidated [*S] Standalone |
Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
---|
Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High | 3.20 3.89 |
Week Low/High | 3.20 4.00 |
Month Low/High | 3.20 4.00 |
Year Low/High | 3.20 10.00 |
All time Low/High | 0.36 40.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | -1.80% | % | -0.27 | -0.18% |
1 Month | -0.78% | % | 1.16 | 1.53% |
3 Month | -6.60% | % | 2.99 | 3.51% |
6 Month | -3.29% | % | 14.26 | 15.85% |
1 Year | -55.32% | % | 16.70 | 16.77% |
3 Year | % | % | 73.35 | 74.99% |
Date | Client Name | Exchange | Transaction | Quantity | Price |
---|---|---|---|---|---|
14-12-2022 | SYEDUMAR | BSE | SELL | 73500 | 5.66 |
06-12-2022 | N L RUNGTA HUF | BSE | SELL | 128500 | 5.28 |
06-12-2022 | N L RUNGTA HUF | BSE | BUY | 30000 | 5.30 |
06-12-2022 | PARESH DHIRAJLAL SHAH | BSE | BUY | 67776 | 5.30 |
06-12-2022 | PARESH DHIRAJLAL SHAH | BSE | SELL | 50002 | 5.30 |
02-12-2022 | DEEPA NAVIN PAMNANI | BSE | SELL | 110721 | 4.39 |
02-12-2022 | DINESH KUMAR JAIN | BSE | SELL | 180000 | 4.81 |
02-12-2022 | MADHUDEVI SANJAY BUCHA | BSE | SELL | 100001 | 4.47 |
02-12-2022 | N L RUNGTA HUF | BSE | BUY | 104500 | 4.47 |
02-12-2022 | N L RUNGTA HUF | BSE | SELL | 40000 | 4.80 |
Load More |
Name | Price(In Rs) | Chg(%) | Mkt Cap(Rs Cr) | Sales(Rs Cr) | Profit(Rs Cr) | EPS(Rs) | P/E(x) |
---|
Category | Share(%) |
---|---|
Promoter | 0.00 |
Financial Institutions Banks | 0.00 |
Foreign Institutional Investors | 0.00 |
Insurance Companies | 0.00 |
Mutual Funds Uti | 0.00 |
Other Institutional Investors | 0.00 |
Indian Public | 93.67 |
Others Non Institutional Investors | 6.33 |
Custodians | 0.00 |
Announcement Date | Purpose | From | To | Remarks |
---|---|---|---|---|
Data Not Found |
Search for Price History
Date | Open | High | Low | Close | Shares | Trades |
---|---|---|---|---|---|---|
Data Not Found |
Load more
Non-Exec. & Independent Dir. : Gagan Juneja
Independent Director : Mohd. Shahbaz Alam
Additional Director : Sitaben S Patel
Additional Director : Rajeev Mehra
Registered Office: B-9 & 10 Laxmi Towers, L S C Block-C Saraswati Vihar,Delhi,New Delhi-110034 Ph: 91-011-2701 1428